Molnupiravir, nirmatrelvir/ritonavir, or sotrovimab for high-risk COVID-19 patients infected by the omicron variant: hospitalization, mortality, and time until negative …
L Cegolon, R Pol, O Simonetti, F Larese Filon… - Pharmaceuticals, 2023 - mdpi.com
Background. Several drugs which are easy to administer in outpatient settings have been
authorized and endorsed for high-risk COVID-19 patients with mild–moderate disease to …
authorized and endorsed for high-risk COVID-19 patients with mild–moderate disease to …
Real-world effectiveness of nirmatrelvir–ritonavir against BA. 4 and BA. 5 omicron SARS-CoV-2 variants
Over the past year of the COVID-19 pandemic, populations worldwide have been facing the
constant threat of the SARS-CoV-2 omicron variant and its sublineages, and the high …
constant threat of the SARS-CoV-2 omicron variant and its sublineages, and the high …
Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales …
A Evans, C Qi, JO Adebayo, J Underwood, J Coulson… - Journal of Infection, 2023 - Elsevier
Objective To compare the effectiveness of molnupiravir, nirmatrelvir-ritonavir, and
sotrovimab with no treatment in preventing hospital admission or death in higher-risk …
sotrovimab with no treatment in preventing hospital admission or death in higher-risk …
Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system
JA Lewnard, JM McLaughlin, D Malden… - The Lancet Infectious …, 2023 - thelancet.com
Background In the USA, oral nirmatrelvir–ritonavir is authorised for use in patients aged 12
years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …
years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …
Associations of nirmatrelvir-ritonavir treatment with death and clinical improvement in hospitalized patients with COVID-19 during the Omicron wave in Beijing, China …
X Han, C Li, X Yuan, J Cui, Z Han, J Meng… - Annals of …, 2024 - Taylor & Francis
Background The effectiveness of nirmatrelvir–ritonavir has mainly been shown in non-
hospitalized patients with mild-to-moderate coronavirus disease 2019 (COVID-19). The real …
hospitalized patients with mild-to-moderate coronavirus disease 2019 (COVID-19). The real …
Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients
A Jayk Bernal, MM Gomes da Silva… - … England Journal of …, 2022 - Mass Medical Soc
Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …
Is azvudine comparable to nirmatrelvir-ritonavir in real-world efficacy and safety for hospitalized patients with COVID-19? A retrospective cohort study
Q Zhao, B Zheng, B Han, P Feng, Z Xia, H Jiang… - Infectious Diseases and …, 2023 - Springer
Introduction Azvudine and nirmatrelvir-ritonavir are more extensively used to treat COVID-19
in China due to their earlier approval by the National Medical Products Administration …
in China due to their earlier approval by the National Medical Products Administration …
Efficacy and safety of molnupiravir for the treatment of non-hospitalized adults with mild COVID-19: a randomized, open-label, parallel-group phase 3 trial
SK Tippabhotla, DS Lahiri, C Kandi - 2022 - papers.ssrn.com
Background: Molnupiravir is an oral prodrug with antiviral activity against severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2). Molnupiravir was initially developed for …
respiratory syndrome coronavirus-2 (SARS-CoV-2). Molnupiravir was initially developed for …
Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter …
X Han, D Gao, C Li, X Yuan, J Cui, W Zhao, F Xie… - BMC Infectious …, 2024 - Springer
Background and aim Two oral antivirals (Nirmatrelvir-ritonavir and Azvudine) are widely
used in China practice during the Omicron wave of the pandemic. However, little evidence …
used in China practice during the Omicron wave of the pandemic. However, little evidence …
[HTML][HTML] Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19–Related Hospitalization and Mortality: A Systematic Literature Review
AS Cha-Silva, MB Gavaghan, T Bergroth… - American Journal of …, 2024 - journals.lww.com
Background: Nirmatrelvir/ritonavir (NMV/r) is an oral antiviral drug used to treat mild-to-
moderate coronavirus disease 2019 (COVID-19) in patients aged 12 years or older at high …
moderate coronavirus disease 2019 (COVID-19) in patients aged 12 years or older at high …